Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Addressing the challenges of the clinical application of pharmacogenetic testing.

Literature DB >> 19536122

Addressing the challenges of the clinical application of pharmacogenetic testing.

O N Ikediobi¹, J Shin, R L Nussbaum, K A Phillips, J M Walsh, U Ladabaum, D Marshall.

Abstract

Pharmacogenomics aims to use molecular genetic markers to predict treatment outcome. Indeed, within the past decade there has been a rapid emergence of pharmacogenetic tests to aid clinicians in predicting efficacy or toxicity for some drugs. Despite this major advance in therapeutic drug management, there remain challenges to the appropriate use of pharmacogenetic tests. We discuss UGT1A1 pharmacogenetic testing to illustrate the knowledge gaps impeding widespread use of pharmacogenetic tests in the clinical setting.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Year: 2009 PMID： 19536122 PMCID： PMC2910521 DOI： 10.1038/clpt.2009.30

Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875

7 in total

Review 1. Pharmacogenetics of Gilbert's syndrome.

Authors: Christian P Strassburg
Journal: Pharmacogenomics Date: 2008-06 Impact factor: 2.533

2. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

Authors: Y Ando; H Saka; M Ando; T Sawa; K Muro; H Ueoka; A Yokoyama; S Saitoh; K Shimokata; Y Hasegawa
Journal: Cancer Res Date: 2000-12-15 Impact factor: 12.701

Review 3. Delivery of genomic medicine for common chronic adult diseases: a systematic review.

Authors: Maren T Scheuner; Pauline Sieverding; Paul G Shekelle
Journal: JAMA Date: 2008-03-19 Impact factor: 56.272

4. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

Authors: Federico Innocenti; Samir D Undevia; Lalitha Iyer; Pei Xian Chen; Soma Das; Masha Kocherginsky; Theodore Karrison; Linda Janisch; Jacqueline Ramírez; Charles M Rudin; Everett E Vokes; Mark J Ratain
Journal: J Clin Oncol Date: 2004-03-08 Impact factor: 44.544

5. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

Authors: Janelle M Hoskins; Richard M Goldberg; Pingping Qu; Joseph G Ibrahim; Howard L McLeod
Journal: J Natl Cancer Inst Date: 2007-08-28 Impact factor: 13.506

6. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

Authors: E Beutler; T Gelbart; A Demina
Journal: Proc Natl Acad Sci U S A Date: 1998-07-07 Impact factor: 11.205

7. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

Authors:
Journal: Genet Med Date: 2009-01 Impact factor: 8.822

7 in total

11 in total

1. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Authors: M V Relling; T E Klein
Journal: Clin Pharmacol Ther Date: 2011-01-26 Impact factor: 6.875

Review 2. The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?

Authors: Mafalda M Dias; Michael J Sorich; Andrew Rowland; Michael D Wiese; Ross A McKinnon
Journal: Pharm Res Date: 2017-02-24 Impact factor: 4.200

3. Capacity building for assessing new technologies: approaches to examining personalized medicine in practice.

Authors: Stephanie L Van Bebber; Julia R Trosman; Su-Ying Liang; Grace Wang; Deborah A Marshall; Sara Knight; Kathryn A Phillips
Journal: Per Med Date: 2010-07 Impact factor: 2.512

4. Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists.

Authors: Rachel Mills; Susanne B Haga
Journal: Pharmacogenomics Date: 2013-06 Impact factor: 2.533

Addressing the challenges of the clinical application of pharmacogenetic testing.

Review 1. Pharmacogenetics of Gilbert's syndrome.

2. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

Review 3. Delivery of genomic medicine for common chronic adult diseases: a systematic review.

4. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

5. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

6. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

7. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

1. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Review 2. The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?

3. Capacity building for assessing new technologies: approaches to examining personalized medicine in practice.

4. Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists.

5. Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.

6. Molecular therapy drives patient-centric health care paradigms.

7. Personalized medicine: Striding from genes to medicines.

Review 8. The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions.

9. Analysis of pharmacogenetic traits in two distinct South African populations.

10. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.